t
Abingdon Health plc shareholders passed two resolutions at a General Meeting on 30 October 2025, with 99.82% of votes for the authority to allot shares and 99.66% for the disapplication of pre-emption rights. Application has been made for admission of 57,441,821 new Ordinary Shares to AIM, expected on or around 31 October 2025, increasing the total voting rights to 251,072,642. Additionally, on 30 October 2025, Executive Chairman Chris Hand subscribed for 500,000 shares and Quality and Regulatory Director Candice Vendettuoli subscribed for 33,333 shares, each at 6 pence per share.
| Date | 30 Oct 2025 |
| Time | 09:43:15 |
| Category | AGMs and other meetings |
| ID | 5023F |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
30 October 2025
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Result of General Meeting and Total Voting Rights
Abingdon Health plc (AIM: ABDX) a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, is pleased to announce that, at the General Meeting held earlier today, the Resolutions set out in the Notice of General Meeting contained in the Circular dated 14 October 2025 were duly passed.
Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement made at 5:04 p.m. on 13 October 2025, unless the context requires otherwise.
Result of Meeting
Details of the results of the voting at the General Meeting, including the number of votes for and against the Resolutions proposed, and the number of votes withheld, are set out below. The Resolutions were proposed and passed as one ordinary resolution and one special resolution.
|
Resolution |
For |
Against |
Withheld |
||
|
Votes |
% of votes cast |
Votes |
% of votes cast |
Votes |
|
|
1. Authority to allot shares |
81,408,856 |
99.82 |
144,292 |
0.18 |
23,747 |
|
2. Disapplication of pre-emption rights |
81,247,542 |
99.66 |
273,311 |
0.34 |
56,042 |
The total number of votes received were 163,074,001. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The passing of the Resolutions is one of the conditions to completion of the Fundraising, and as a result of the votes cast in their favour, that particular condition has been satisfied. Completion of the Fundraising remains conditional upon Admission, which is expected to occur on or around 31 October 2025.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for admission of the 57,441,821 new Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings in the new Ordinary Shares will commence at 8.00 a.m. on or around 31 October 2025.
Following Admission, the Company's issued ordinary share capital will comprise 251,072,642 Ordinary Shares, with no shares held in treasury. Therefore, the number of Total Voting Rights in the Company will be 251,072,642, and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Director and PDMR Shareholdings
Following completion of the Fundraising, the following Directors are interested in the following:
|
Director / PDMR |
Position |
Existing beneficial interest in Ordinary Shares |
% of current share capital |
New Ordinary Shares subscribed for |
Ordinary Shares after Fundraise |
% of Enlarged Share Capital |
|
Chris |
Executive Chairman |
13,178,467 |
6.8 |
500,000 |
13,678,467 |
5.4% |
|
Candice Vendettuoli |
Quality and Regulatory Director |
- |
- |
33,333 |
33,333 |
0.01% |
Enquiries:
|
Abingdon Health plc |
|||
|
Chris Hand, Executive Chairman
|
Via Walbrook PR |
||
|
Tom Hayes, Chief Financial Officer
|
|
||
|
|
|
||
|
Zeus (Sole Broker and Nominated Adviser) |
Tel: +44 (0)20 3829 5000 |
||
|
Antonio Bossi / Darshan Patel / Jacob Walker (Corporate Finance) |
|
||
|
Nick Searle / Fraser Marshall (Corporate Broking)
|
|
||
|
|
|
||
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or [email protected] |
||
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
|
|
|
||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name |
Dr Chris Hand
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Chairman |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Abingdon Health plc |
|||
|
b)
|
LEI
|
213800XFI4WV3FBILO20
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.025 pence each
|
|||
|
|
|
||||
|
Identification code |
GB00BLF79J41 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
6 pence per share
|
500,000
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
500,000 |
||||
|
|
|
||||
|
- Price |
6 pence per share |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
30 October 2025 |
|||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name |
Candice Vendettuoli |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Quality and Regulatory Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Abingdon Health plc |
|||
|
b)
|
LEI
|
213800XFI4WV3FBILO20
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.025 pence each
|
|||
|
|
|
||||
|
Identification code |
GB00BLF79J41 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
6 pence per share
|
33,333
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
33,333 |
||||
|
|
|
||||
|
- Price |
6 pence per share |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
30 October 2025 |
|||
|
f) |
Place of the transaction |
London Stock Exchange, AIM |
|||
About Abingdon Health plc
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success". Abingdon Analytical Ltd offers performance evaluation for lateral flow and other in vitro diagnostic assays from its Doncaster laboratory.
Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com.